Regarding cancers expressing/overexpressing wild-type EGFR, such as head and neck, prostate, and ovarian cancer, which are innately resistant to EGFR TKIs, a new interpretation is that these types of cancers are more dependent on EGFR's KID function for survival rather than on its kinase activity for growth. This evidence concerns the gene EGFR and ovarian carcinoma.